The University of California, San Francisco (UCSF) has signed an alliance with international pharmaceutical company Sanofi (EURONEXT: SAN and NYSE: SNY) to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes. The $3.1 ...

(University of California - San Francisco) The University of California, San Francisco has signed an alliance with international pharmaceutical company Sanofi to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

Sanofi (EURONEXT : SAN and NYSE : SNY) confirmed today its decades-long commitment to the fight against malaria at the opening of 10th Edition of the Pan- African Conference against Malaria. The 10th Edition of this conference gathers together the directors of 34 African National Malaria Control Programs (NMCPs), representatives ...

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced the introduction of a new education campaign designed to help answer parents' questions about immunization and to offer health-care professionals a reference tool to supplement their discussions about vaccination with patients. The site contains useful ...

November 02, 2011, Seoul, S. Korea One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The ...

(Institut Pasteur Korea) One of the most common and serious infectious diseases, hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea, and the Korean arm of the leading global health-care company, Sanofi-Aventis Korea. The goal is to develop and ...

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R)...

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis ...

Sanofi announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc., for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.

French drugs group Sanofi said Friday that its vaccine against dengue, a mosquito-borne infection that kills thousands of people around the world each year, could be launched in about four years.

Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes ...

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of Fluzone Intradermal (Influenza Virus Vaccine). Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 ...